Literature DB >> 19841152

Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria.

Patrick D Mauldin1, Cassandra D Salgado, Ida Solhøj Hansen, Darshana T Durup, John A Bosso.   

Abstract

Determination of the attributable hospital cost and length of stay (LOS) are of critical importance for patients, providers, and payers who must make rational and informed decisions about patient care and the allocation of resources. The objective of the present study was to determine the additional total hospital cost and LOS attributable to health care-associated infections (HAIs) caused by antibiotic-resistant, gram-negative (GN) pathogens. A single-center, retrospective, observational comparative cohort study was performed. The study involved 662 patients admitted from 2000 to 2008 who developed HAIs caused by one of following pathogens: Acinetobacter spp., Enterobacter spp., Escherichia coli, Klebsiella spp., or Pseudomonas spp. The attributable total hospital cost and LOS for HAIs caused by antibiotic-resistant GN pathogens were determined by comparison with the hospital costs and LOS for a control group with HAIs due to antibiotic-susceptible GN pathogens. Statistical analyses were conducted by using univariate and multivariate analyses. Twenty-nine percent of the HAIs were caused by resistant GN pathogens, and almost 16% involved a multidrug-resistant GN pathogen. The additional total hospital cost and LOS attributable to antibiotic-resistant HAIs caused by GN pathogens were 29.3% (P < 0.0001; 95% confidence interval, 16.23 to 42.35) and 23.8% (P = 0.0003; 95% confidence interval, 11.01 to 36.56) higher than those attributable to HAIs caused by antibiotic-susceptible GN pathogens, respectively. Significant covariates in the multivariate analysis were age >or=12 years, pneumonia, intensive care unit stay, and neutropenia. HAIs caused by antibiotic-resistant GN pathogens were associated with significantly higher total hospital costs and increased LOSs compared to those caused by their susceptible counterparts. This information should be used to assess the potential cost-efficacy of interventions aimed at the prevention of such infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841152      PMCID: PMC2798544          DOI: 10.1128/AAC.01041-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species.

Authors:  Sara E Cosgrove; Keith S Kaye; George M Eliopoulous; Yehuda Carmeli
Journal:  Arch Intern Med       Date:  2002-01-28

2.  Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites.

Authors:  James J Rahal; Carl Urban; Sorana Segal-Maurer
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

3.  The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay.

Authors: 
Journal:  Infect Control Hosp Epidemiol       Date:  2002-02       Impact factor: 3.254

Review 4.  Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop.

Authors:  D Howard; R Cordell; J E McGowan; R M Packard; R D Scott; S L Solomon
Journal:  Clin Infect Dis       Date:  2001-09-26       Impact factor: 9.079

5.  Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.

Authors:  Ebbing Lautenbach; Mark G Weiner; Irving Nachamkin; Warren B Bilker; Angela Sheridan; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2006-08-21       Impact factor: 3.254

6.  Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact.

Authors:  Leanne B Gasink; Neil O Fishman; Mark G Weiner; Irving Nachamkin; Warren B Bilker; Ebbing Lautenbach
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

7.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

8.  Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.

Authors:  Su Young Lee; Srividya Kotapati; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Journal:  Infect Control Hosp Epidemiol       Date:  2006-10-23       Impact factor: 3.254

Review 9.  Resistance patterns among nosocomial pathogens: trends over the past few years.

Authors:  R N Jones
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

10.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.

Authors:  E Lautenbach; J B Patel; W B Bilker; P H Edelstein; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

View more
  95 in total

1.  Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.

Authors:  Pratik Bhagunde; Kai-Tai Chang; Elizabeth B Hirsch; Kimberly R Ledesma; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

2.  Estimating the length of hospitalization attributable to multidrug antibiotic resistance.

Authors:  Stijn Blot; Dominique Vandijck; Christelle Lizy; Lieven Annemans; Dirk Vogelaers
Journal:  Antimicrob Agents Chemother       Date:  2010-09       Impact factor: 5.191

3.  Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.

Authors:  Caroline G Elmer-Lyon; Judy A Streit; Elizabeth B Takacs; Patrick P Ten Eyck; Catherine S Bradley
Journal:  Int Urogynecol J       Date:  2019-06-20       Impact factor: 2.894

4.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 5.  Overview on the role of heavy metals tolerance on developing antibiotic resistance in both Gram-negative and Gram-positive bacteria.

Authors:  Raju Biswas; Urmi Halder; Ashutosh Kabiraj; Amit Mondal; Rajib Bandopadhyay
Journal:  Arch Microbiol       Date:  2021-04-02       Impact factor: 2.552

6.  Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients.

Authors:  Aaron S Hess; Michael Kleinberg; John D Sorkin; Giora Netzer; Jennifer K Johnson; Michelle Shardell; Kerri A Thom; Anthony D Harris; Mary-Claire Roghmann
Journal:  Diagn Microbiol Infect Dis       Date:  2014-01-30       Impact factor: 2.803

7.  Accumulation of Pyrimidine Intermediate Orotate Decreases Virulence Factor Production in Pseudomonas aeruginosa.

Authors:  Abdurahman Niazy; Lee E Hughes
Journal:  Curr Microbiol       Date:  2015-04-28       Impact factor: 2.188

8.  Educating Patients on Unnecessary Antibiotics: Personalizing Potential Harm Aids Patient Understanding.

Authors:  Benjamin J Miller; Kathryn A Carson; Sara Keller
Journal:  J Am Board Fam Med       Date:  2020 Nov-Dec       Impact factor: 2.657

Review 9.  Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond?

Authors:  Tianhong Dai; Asheesh Gupta; Clinton K Murray; Mark S Vrahas; George P Tegos; Michael R Hamblin
Journal:  Drug Resist Updat       Date:  2012-07-28       Impact factor: 18.500

10.  The effects of circumcision on the penis microbiome.

Authors:  Lance B Price; Cindy M Liu; Kristine E Johnson; Maliha Aziz; Matthew K Lau; Jolene Bowers; Jacques Ravel; Paul S Keim; David Serwadda; Maria J Wawer; Ronald H Gray
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.